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income, geographic region, insurance coverage, year of first admission, diabetes-
care variables such as foot checks and diet modification, and severity factors, such
as number of diagnoses andwhether any procedurewas performed during the first
admission. RESULTS: Over the years 1999 to 2009, out of 7.27 million patients with
a diabetes-related hospital admission, 37.62% had a diabetes-related readmission.
Patients in the Midwest compared to patients in the West were more likely to be
readmitted (OR2.13; 95% CI: 2.12-2.14). Patients in the higher income group were
more likely to be readmitted than those in the lower income group (OR2.13; 95%
CI: 2.12-2.16). Patients who did not follow the recommended diet for diabetes were
more likely to be readmitted than those who followed the recommended diet for
diabetes (OR1.45; 95% CI: 1.43-1.46). Severity indicators also had statistically sig-
nificant coefficients(p-value0.0001). CONCLUSIONS: Diabetes treatment without
diet modification, regional disparities and income are significant predictors of in-
creased hospital readmissions. Policy interventions should be planned accordingly
and diet modification should be stressed in clinical practice to decrease the hospi-
tal readmission rate.
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OBJECTIVES: The purpose of the study was to assess the clinical and economic
impact of a pharmacist-ledmedicationmanagement program (MMP) implemented
at a regional health plan. Diabetes control (i.e. A1Cmeasures) and healthcare costs
were compared between intervention and control patients with two years of
follow-up.METHODS: Eligible participants in theMMPmet the following criteria: 1)
diagnosedwith diabetes for at least one-year; 2) anA1C level7.5% at baseline; 3) at
least sixmonths of enrollment prior to baseline; 4) continuous enrollment through-
out the study interval; (5) 18-63 years of age; and; 6) at least one diabeticmedication
claimprior to and after enrollment. The enrollees and controlswerematched 1:1 by
age, gender, baseline A1C, and Charlson comorbidity index. Patients were required
to participate in monthly follow-up visits with a pharmacist; in exchange, they
received copay waivers for all diabetic medications and supplies. To assess A1C
changes, paired t-testswere usedwithin groups and independent t-testswere used
for pairwise differences. Cost data were bootstrapped to determine significance.
RESULTS: A total of 139 patients met inclusion criteria with at least two years of
follow-up. MMP patients had an A1C decrease of 1.16 while control patients had a
decrease of 0.73 (P0.03). Average per member per month (PMPM) costs increased
by 17% and 69% in the MMP and control groups, respectively. Cost increase in the
MMP group wasmainly attributable to prescription and outpatient costs; however,
this was largely offset by a 64% decrease in inpatient costs (95% CI, -$2844.29 to
-$582.04). CONCLUSIONS: Two years of follow-up revealed MMP patients signifi-
cantly improved clinical measures compared to the matched control group. Over-
all, costs in both groups increased but the extent of cost increases were much
greater in the control group. The significant decrease in inpatient costs highlights
an opportunity for savings long-term.
PDB105
PAYOR AND PRESCRIBER FEASIBILITY ASSESSMENT OF A PHARMACY BENEFIT
MANAGEMENT (PBM) DIABETES PROGRAM UTILIZING PHARMACIST-ADVISED
SELF-ADJUSTED BASAL INSULIN
Hamid G1, Schrader BJ1, Agatep BC1, Vazhappilly JJ1, Herrera V2, Dalal MR3, Stanek EJ1,
Berria R3, Pendergrass M4, Charland SL1
1Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, MD, USA, 2Medco
Research Institute, LLC, Medco Health Solutions, Inc., Franklin Lakes, NJ, USA, 3Sanofi-Aventis
U.S., BRIDGEWATER, NJ, USA, 4Medco Health Solutions, Inc., Fort Worth, TX, USA
OBJECTIVES: Assess feasibility of instituting a PBM program engaging pharmacists
as prescriber-extenders for care of patients with type 2 diabetes mellitus (T2DM).
METHODS: Surveys included 146 payors (15 questions) and 2000 T2DM prescribers
(Internal Medicine [IM], Endocrinologists/Diabetes specialists [ENDO/DS] and Fam-
ily practitioners [FP]; (30 questions). After a description of a pharmacist-managed
basal insulin initiation/intensification program, the survey evaluated interest and
importance of programcomponents including: adherence reports, format/content/
frequency of reports, drug spend, care/management of T2DM, access to care, pa-
tient education/counseling, pharmacist training, and additional management
tools. Statistical comparisons were done by chi-square or Wilcoxon test analysis.
RESULTS: Payor response rate was 13%. They included large (approx 1M), young
(age 354) membership in the Northeast. They believe prescribers will be inter-
ested in receiving T2DMmedication adherence reports (100%) and participating in
the program (68%). Importance was assigned to increased access of care (95%) and
management of patients (100%), but less-so on pharmacist training (53%). The
prescriber response ratewas 7%: 70% ENDO/DS and 29% IM/FP. Compared to ENDO/
DS, more IM/FP believe the program would improve overall care (64% vs 38%),
increase patient education/counseling (57% vs 33%), andwanted T2DMmedication
adherence reports (76% vs 40%) [all p0.05]. More IM/FP (43%) than ENDO/DS (19%,
p0.05) state theywould refer patients to the program. Formost prescribers, finan-
cial compensation was not a driving factor, while contact of pharmacist/patient
contact/dialog was important. Approximately 60% of IM/FP and 40% of ENDO/DS
were willing to share blood pressure, lipid, and hemoglobin A1C values with
pharmacists.CONCLUSIONS: Payors are interested in improving care andmanage-
ment of T2DM and endorse a PBM-based pharmacist physician-extender program.
Primary care prescribers were more supportive of the program, willing to share
data, and likely to refer patients than Endocrinologists/Diabetes specialists. Con-
sidering response bias, overall, the program is feasible and has been implemented.
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OBJECTIVES: Long acting insulin agents (LG) have shown several advantages com-
pared to other anti-diabetic therapies in treatment of diabetes, however their real
world impact at the national level is unknown. The objectives of the study were to
assess the impact of LG on HRQoL, health care expenditures and utilization among
diabetic patients receiving insulin agents. METHODS: A longitudinal study was
conducted including diabetic patients  18 years receiving insulin agents using
data from 2006-2008 Medical Expenditures Panel Survey (MEPS). We compared
diabetic patients receiving LG (Insulin glargine and Insulin detemir) to those re-
ceiving other insulin agents (OG). HRQoL was assessed using Short Form 36 (SF-36)
survey [Physical component score (PCS) andMental component score (MCS)], while
expenditures and utilization were evaluated in terms of ambulatory visits, emer-
gency room visits, inpatient stays and prescription drugs. Multivariate linear re-
gression, negative binomial regression and two-part models were used for assess-
ing impact onHRQoL, expenditures and utilization as appropriate. RESULTS:Out of
7.1million diabetic patients receiving insulin agents, 47.2% (CI:46.1-48.3%) received
LG. There was no statistical significant improvement in the PCS and MCS between
these groups, however, there was a favorable trend on PCS (2.6,CI:(-2.2)-7.3) in
patients receiving LG. Patients receiving LG showed a 43% (CI:4.9-55.5%) reduction
in total health care expenditures, with 43% reduction in ambulatory visits (CI:4.9-
66.4%), and 49% reduction in inpatient stays (CI:3.9-73.3%) as compared to OG
among patients having expenditures. Patients receiving LG were associated with
reduced ambulatory care visits (0.68,CI:0.47-0.98), prescription drug count (0.48,CI:
0.30-0.89) and inpatient days (0.73,CI:0.58-0.91) as compared to OG among patients
having utilization. CONCLUSIONS: Compared to OG, LG showed improvement in
HRQoL and were associated with lower health care expenditures and utilization.
Hence, LG can play an important role in overcoming the barrier towards insulin use
and thereby help in effectively treating diabetes mellitus patients.
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OBJECTIVES: Compare patient characteristics, medication use, diabetes-related
charges, and resource utilization between patients with Type 2 diabetes (T2DM)
based upon classification as “adherent” or “non-adherent.” METHODS: Data were
obtained from the i3 inVision™ databases from January 1, 2006 through June 30,
2010. The analyses focused on patients who initiated therapy on antidiabetic med-
ication(s) and were followed for 2 years post initiation (N48,592). Patients were
categorized as being adherent (N17,266) or non-adherent (N31,000) based upon
amedication possession ratio (MPR) threshold of 0.80. The analyses are descriptive
in nature. RESULTS: Themean age of patients in this study was 53 years, with 54%
of the populationmale and 59% residing in the Southern region of the US. Adherent
patientswere less likely to augment their intent-to-treat (ITT)medication(s) (6% vs.
25%; P0.0001), switchmedications (2% vs. 16%; P0.0001) or have a gap in therapy
of at least 60 days (9% vs. 47%; P0.0001). Adherent patients were found to be less
likely to be hospitalized in the post-period (17% vs. 21%; P0.0001). Despite signif-
icantly higher diabetes-related drug charges ($1690 vs. $1232; P0.0001), adherent
patients had significantly lower total diabetes-related costs ($6592 vs. $6,863;
P0.0221). For a subset of patientswho had a valid HbA1cmeasurement in both the
pre and post-period (N7862), results revealed that adherent patients had a signif-
icantly larger reduction in their HbA1c values (-0.72 vs. -0.63; P0.0333) despite
having a significantly lower HbA1c value prior to initiation on therapy (7.58 vs. 7.95;
P0.0001). Non-adherent patients who discontinued their ITT medication(s)
(N288), however, had a mean HbA1c (6.32; SD1.30) which is below the recom-
mended target level for glycemic control, and suggests a valid clinical reason for
discontinuation. CONCLUSIONS: Patient characteristics, treatment patterns, and
outcomes differ significantly between adherent and non-adherent patients.
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OBJECTIVES: To compare the performance of Health-related Quality of Life Comor-
bidity Index (HRQL-CI), D’Hoore Comorbidity Index, Elixhauser Comorbidity Mea-
sures, and Disease Count in risk-adjusting HRQL in diabetes patients. METHODS:
The 2008Medical Expenditure Panel Survey (MEPS) including adults18 yearswith
diagnosis of diabetes (ICD9  250) was used to evaluate the performance of four
comorbidity measures for risk-adjusting Short Form-12 Physical Component Score
(PCS) and Mental Component Score (MCS). The comorbidity measures included
D’Hoore adaptation of Charlson comorbidity index (identified using 3 digit ICD9
codes), Elixhauser Comorbidity Measures (identified using 3 digit ICD9 codes),
HRQL-CI (identified using Agency for Healthcare Research and Quality Clinical
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